Drug news
Sanofi files Toujeo ([rDNA origin] injection, 300 U/mL) at EMA and FDA for Diabetes
On May 27, 2014, the European Medicines Agency (EMA) accepted Sanofi�s marketing authorization dossier for insulin glargine (rDNA origin) injection 300 U/mL, for EU countries. Sanofi has submitted the New Drug Application (NDA) for insulin glargine [rDNA origin] injection, 300 U/mL to the FDA. The formal acceptance of the submission is pending.
Toujeo is the intended trade name for insulin glargine [rDNA origin] injection, 300 U/mL; formerly abbreviated as �U300".
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins